Clinical Trial Confirms Low-Dose Aspirin Reduces Colorectal Cancer Recurrence in Genetically Targeted Patients

A groundbreaking Phase 3 clinical trial led by the Karolinska Institutet has demonstrated that daily low-dose aspirin can significantly lower the risk of cancer recurrence in colorectal cancer patients, provided their tumors harbor specific mutations in the PI3K signaling pathway. The ALASCCA trial, which monitored over 3,500 patients across the Nordic region, found that aspirin reduced the likelihood of disease return by roughly 50% for approximately 37% of the colorectal cancer population. While the study highlights a potential “precision medicine” role for the century-old drug, researchers also noted a slight increase in severe adverse events among those receiving the treatment. These findings could signal a shift toward routine genomic testing for colorectal cancer patients to determine if inexpensive aspirin therapy should be integrated into post-surgical care.

STOCKHOLM — In what researchers are calling a milestone for precision oncology, a common and inexpensive household medication—aspirin—has been shown to act as a powerful deterrent against the return of colorectal cancer in patients with a specific genetic profile.

According to results from the ALASCCA (Adjuvant Low-Dose Aspirin in Colorectal Cancer) trial, patients whose tumors carried mutations in the PI3K (phosphatidylinositol 3-kinase) signaling pathway saw their risk of cancer recurrence cut in half when taking a daily 160 mg dose of aspirin following surgery. The findings, presented at the 2025 Gastrointestinal Cancers Symposium and recently detailed in the New England Journal of Medicine, provide the first randomized clinical evidence to support years of observational data suggesting aspirin’s potential as a cancer therapeutic.

A Targeted Breakthrough in the PI3K Pathway

The PI3K pathway is a critical cellular engine that regulates growth, survival, and metabolism. In roughly one-third of colorectal cancer cases, this pathway is hijacked by mutations—most notably in the PIK3CA gene—causing cells to proliferate uncontrollably.

The ALASCCA investigators screened 3,508 patients across 33 hospitals in Sweden, Norway, Denmark, and Finland. They identified that 37% of these patients possessed the necessary genetic alterations to be included in the randomized portion of the study. These participants were divided into two groups:

• Group A: Patients with PIK3CA mutations in the “hotspot” regions of exon 9 or exon 20.
• Group B: Patients with other PI3K pathway drivers, such as PIK3R1 or PTEN alterations.

“Aspirin is being tested here in a completely new context as a precision medicine treatment,” said Dr. Anna Martling, the study’s lead author and a professor of surgery at the Karolinska Institutet. “This is a clear example of how we can use genetic information to personalize treatment and at the same time save both resources and suffering.”

Analyzing the Data: Recurrence and Survival

The trial results were starkly divided by the presence of these genetic markers. For patients in Group A (the PIK3CA hotspot group), the three-year recurrence rate for those taking aspirin was 7.7%, compared to 14.1% for those on the placebo. In Group B, the results were even more pronounced, with recurrence rates of 7.7% for the aspirin group versus 16.8% for the placebo group.

Mathematically, this represents a hazard ratio of 0.49 for Group A and 0.42 for Group B, effectively indicating a 51% to 58% reduction in the risk of the cancer returning within the three-year window. Furthermore, the estimated disease-free survival (DFS) at the three-year mark reached approximately 89% for those treated with aspirin, a notable improvement over the 79% to 81% observed in the placebo arms.

Historical Context and the Mechanism of Action

Aspirin’s history as a medicinal tool dates back to antiquity, with Hippocrates documenting the use of willow bark—the natural source of salicin—to treat pain and fever as early as 400 B.C. However, its modern iteration as acetylsalicylic acid was not stabilized until 1897 by Felix Hoffmann at Bayer. Throughout the 20th century, it evolved from a simple analgesic to a cornerstone of cardiovascular health after researchers discovered its ability to inhibit platelet aggregation, thereby preventing heart attacks and strokes.

The link between aspirin and cancer prevention first emerged in the 1980s and 90s, when large-scale observational studies of cardiovascular patients noticed an unexpected drop in colorectal cancer rates among long-term aspirin users.

Biologically, researchers believe aspirin works against cancer through a “multi-pronged” approach. It inhibits the cyclooxygenase-2 (COX-2) enzyme, which is often overexpressed in tumors and linked to inflammation that promotes cancer growth. Additionally, by limiting platelet activity, aspirin may prevent cancer cells from using platelets as “shields” to hide from the immune system while traveling through the bloodstream.

Weighing the Risks and Accessibility

Despite the positive data, the medical community remains cautious about the universal application of aspirin in cancer care. The ALASCCA trial reported that 16.8% of patients in the aspirin group experienced severe adverse events, such as gastrointestinal bleeding or post-operative complications, compared to 11.6% in the placebo group.

“In a small proportion of people, aspirin can cause serious side effects,” noted Professor Ruth Langley of University College London, who is leading a separate, ongoing trial called Add-Aspirin. “It is important to understand which people with cancer are likely to benefit.”

The primary appeal of the ALASCCA findings lies in the extreme cost-effectiveness of the intervention. While modern immunotherapy or targeted biologics can cost tens of thousands of dollars per month, a daily dose of aspirin costs mere cents.

Colorectal cancer remains the second leading cause of cancer-related deaths globally, with nearly two million new cases diagnosed annually. In the United States alone, the American Cancer Society estimated over 150,000 new diagnoses for 2024, with an alarming rise in cases among adults under age 55.

As genomic testing becomes more standardized in oncology, experts suggest that identifying PIK3CA mutations could become a routine part of the post-surgical checklist, allowing doctors to prescribe a “precision” dose of one of the world’s oldest drugs to those most likely to stay cancer-free because of it.